PRGO vs UCFI
PRGO: A struggling diversified consumer and prescription healthcare manufacturer navigating portfolio restructuring and strategic divestitures amid margin pressure and competitive headwinds. UCFI: An AI-powered health food technology company blending biotech innovation with traditional Chinese medicine to develop premium nutritional products for the Chinese market.
Side-by-side fundamentals
| Metric | PRGO | UCFI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.47 | $5.51 | |
| Market cap as of 2026-07-23 | $1.5B | $288M | |
| P/E as of 2026-07-23 | n/a | 66.26 | |
| PEG as of 2026-07-23 | -0.00 | n/a | |
| Net margin as of 2026-07-23 | -43.5% | +30.3% | UCFI higher |
| Gross margin as of 2026-07-23 | +34.2% | +66.3% | UCFI higher |
| Operating margin as of 2026-07-23 | -36.9% | +42.4% | UCFI higher |
| ROE as of 2026-07-23 | -50.6% | +23.0% | UCFI higher |
| ROA as of 2026-07-23 | -19.8% | +8.1% | UCFI higher |
| Debt / equity as of 2026-07-23 | 1.45 | 0.18 | UCFI lower |
| Revenue growth (YoY) as of 2026-07-23 | -3.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -1.5% | n/a | |
| Dividend yield as of 2026-07-23 | +11.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.53 | -0.38 | |
| 1-year return as of 2026-07-22 close | -62.0% | -48.5% | UCFI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.